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Sdiagnosed at the intrathoracic and asymptomatic stage,
within 2 years of surgery, when potentially curative
intervention still is possible. Other investigators have
shown that, in patients with previously resected lung
cancer, curative surgery for a second lung cancer can be
associated with a 5-year survival rate of 60%.22,23 In this
study, the majority of asymptomatic patients were offered
curative treatment that was associated with a median
survival of more than 5 years, suggesting that efforts
directed toward early intervention are associated with
encouraging survival in a subset of patients with
asymptomatic disease.
There were several limitations to this study. Although
MnDCT can be performed in any setting, the radiologists
at our hospital have extensive experience in interpreting
low-dose and ultra-low-dose images, and this may not be
generalizable to other institutions. MnDCT is unable to
distinguish between new and recurrent lung cancer, a
distinction that is important in terms of prognosis.18,24 In
addition, lead time and length time bias can falsely
improve outcomes for asymptomatic patients detected
early by MnDCT. Finally, because of small numbers and
ongoing follow-up evaluation, this study may not be able
to answer the question of whether MnDCT screening after
lung cancer resection will improve survival in patients
who are in remission.CONCLUSIONS
MnDCT is superior to CXR for the detection of new or
recurrent lung cancer after curative resection of a previous
lung cancer. Themajority of newor recurrent cancerswas de-
tected by MnDCT at an asymptomatic, intrathoracic stage,
within 2 years of surgery. This allowed for the delivery of
curative treatment in themajority of patientswith asymptom-
atic cancer and was associated with long survival.References
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Discussion
Dr Michael T. Jaklitsch (Boston, Mass). Thank you very
much. It is my privilege to discuss this remarkable paper by
Dr Hanna and his colleagues at the University of Toronto on
minimal-dose CT scan for screening of lung cancer recurrence
in those patients who have undergone a successful surgical
operation for early stage lung cancer.
Last year at this meeting the AATS task force for lung cancer
screening and surveillance reported its guidelines for screeningardiovascular Surgery c Volume 147, Number 1 33
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Sfor new populations, but also it was our specific mandate to address
what should be done for screening for surveillance of lung cancer
survivors. We were struck by the paucity of hard scientific data to
draw upon our guidelines and resorted to anecdotal experience of
large centers that had a vast experience, including following the
traditions that were established at the University of Toronto in
the 1980s. I congratulate Dr Hanna and his colleagues for now
providing that surgical evidence that gives meat to the specific
guidelines.
Screening for early stage lung cancer with minimal harm and
maximum benefit is an interaction of several variables, including
the baseline risk of the screened population, the interval of
screening, and the technology of screening. Dr Hanna shows that
this particular population is the highest risk, in fact, a 10% risk
over 5 years. That is twice the risk of what we normally deem as
a high-risk subpopulation of 5% over 5 years, and the NLST
data, which showed a 20% reduction in lung cancer-specific
mortality, had a 2% risk over 5 years.
Furthermore, he has technology that is really impressive.
Dropping that mSv dose down to 0.2, so it really is comparable
to chest x-ray, eliminates the potential harms of the operation,
and they combine this to now introduce the idea of surgical salvage
for early stage lung cancer. So, in fact, they were able to take a
group that would have had a 5-year survival of 50% and raise it
up to 75% through an aggressive surveillance program, and,
furthermore, they established that they were truly curing these
patients.
Is this enough data to change our personal practices today? For
me personally the answer is yes. This single paper presents to me
enough data to say that I want to use aminimal-dose CT scan as my
sole method of screening for recurrence of early stage lung cancer
moving forward. And although he states that minimal-dose CT is
not available at every center in the United States, I was able to take
the specifications that Dr Hanna provided me with in his paper to
my community hospital, and my community hospital assures me
that they can do this. So, at least in the United States of America,
I think that this will have dramatic penetrance.
My specific question, Dr Hanna, is, are there other variables that
come into play that may limit this technology? In particular, one of
the issues is scatter of the x-ray beam. If I have a very heavyset
patient who has a BMI of, say, 40, is this technology going to
work or am I going to have to increase the dose? What if I have
a lot of surgical clips at the hilum? Is that going to produce scatter?
Do you at least have some anecdotal evidence that suggests that
there is a subpopulation in which this will not work?
Thank you for the privilege of discussing this paper.
Dr Hanna. Thank you for your comments, Dr Jaklitsch, and
for taking the time to discuss our paper. Your question is very
important because a lot of radiologists and surgeons ask us about
the accessibility of minimal dose in terms of interpretation. There
are certain limitations to the minimal-dose technology. You
mentioned patients of a particular body habitus and a high BMI.
These are problematic because the noise on the CT scan image
is usually very high and then you cannot really see small detail.
So, in these patients, one would recommend a low-dose CT rather
than minimal-dose CT, at least at our institution. Other limitations
of minimal-dose CTwould be mediastinal imaging. If you have a
patient in whom you are suspecting a high recurrence rate in the34 The Journal of Thoracic and Cardiovascular Surgemediastinum, such as a patient who had a resected tumor where
there was mediastinal involvement or close margins, then our
radiologists feel more comfortable with low-dose CT rather than
minimal-dose CT for the surveillance of these patients. You also
mentioned surgical clips in the area which contribute to the noise
and make minimal-dose CT less sensitive.
Dr Bryan Fitch Meyers (St. Louis, Mo). That was an excellent
paper. I am not likely to be quite as quick to adopt it as Dr Jaklitsch,
but I would be happy to study the process. I have one question:
with early stage (I/II) lung cancer, we expect about 20% to recur
systemically, and about 2% per year to develop a new primary
tumor. If your results presented today are applicable to the general
population of resected lung cancer patients, it would be reassuring
to know that you found the same rate of recurrence and new
primaries in your patients, or did you have an enriched population
by somehow selecting higher-risk patients?
DrHanna. Thank you. This is a very important question. As we
have demonstrated, most of our patients were stage I disease. So
we did find a lower rate of systemic recurrence than what we
expected in a general population of all-comers. However, we do
think that surveillance with minimal-dose CTwill shift those rates
of recurrence or new primary tumors.We do not make a distinction
between recurrence or new primary because we do not think that in
terms of surveillance it matters—these patients are at high risk for
both events.
DrChumyNwogu (Buffalo, NY). My question arises from your
calculation of sensitivity for your minimal-dose CT. What did you
use as your gold standard to do that calculation and did you have
a direct comparison between the regular CT scan and your
minimal-dose CT to see what the differences would be? I think
that would help us tremendously in deciding whether to adopt
this in our daily practices.
Dr Hanna. Thank you very much. It is a very important point.
We did not have a direct comparison between standard-dose CT
and minimal-dose CT, but our gold standard of determining
whether a patient recurred or not was most of the time a
standard-dose CT. When a minimal-dose CT study was deemed
positive by the radiologist and the surgeon, the patient would go
on to a standard-dose CT, and if the findings were suspicious
enough for recurrence, the patient would be biopsied, restaged,
or treated. So most of the time the standard-dose CT was a
reference point to calculate sensitivity.
In patients who we still missed on standard-dose CT, the
eventual development of metastatic disease or local recurrent
disease was considered as the reference point, and in patients
who were treated palliatively because of enough suspicion on
imaging that they had recurrent or metastatic disease, then this
was our reference point. Thank you.
Dr Frank C. Detterbeck (New Haven, Conn). I think this is a
very exciting paper. I am struck, though, that your incidence of
finding a lesion early is quite high, and there are many institutions
that have done CT scans every 6 months or every year. I am sure
you have done that in the past. Have you compared this with either
your prior results or other institutional results at a year, because
those that were found at 3, 6, 9, and 12 months should have shown
up at the yearly scan.
Dr Hanna. Thank you very much. We still do not know exactly
the ideal interval for obtaining scans. Is it 3months or 6months or ary c January 2014
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Syear? We decided on the 3-month and 6-month intervals because it
is part of the international consensus statement, and I do agree that
some of the lesions that we found at 3 months or 6 months could
have been found at a year if we did a yearly scan without much
difference in outcome. So this remains to be studied.
But I do think it is also important to recognize that now there is a
shift in terms of when we diagnose recurrence or new primary after
lung cancer, and it is going to be earlier and earlier.
Dr David J. Sugarbaker (Boston, Mass). Just a quick question,
and that is, what you have really described is the detection of
new primary tumors following initial resection. Particularly in
T2 tumors, the 2 sites of recurrence where long-term therapy is
usually not associated with prolonged survival are, as you said,
mediastinal node disease and distant metastatic disease. So I think
it is important to realize that what you are really talking about
here is screening patients who have had lobar resections or any
resections for lung cancer.The Journal of Thoracic and CSo I am not sure your conclusion about follow-up detection
of metastatic disease is really an accurate description as to
what you have done. And, particularly with the inability of
minimal-dose CT to assess the mediastinum, particularly in
the larger lesions where distant metastatic disease may be
more frequent, I am not sure that minimal dose CT is adequate
for those patients where, again, mediastinal nodal disease can
be the real issue.
Could you comment?
Dr Hanna. Thank you. I do agree with that. I think mini-
mal-dose CT is a good test for detection of a new primary.
However, we realize that these patients are also at risk
for mediastinal disease, and I think the future will hold a
more patient-centered approach to follow-up whereby patients
with a higher risk of distant recurrence will have some other
tests on top of the minimal-dose CT to try and detect that
earlier.ardiovascular Surgery c Volume 147, Number 1 35
